LINC01186: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

Target Name: LINC01186

NCBI ID: G101927574

LINC01186

Other Name(s): long intergenic non-protein coding RNA 1186 | ZNF674-1 | Long intergenic non-protein coding RNA 1186

LINC01186: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

LINC01186 is a long non-coding RNA (lncRNA) molecule that has been identified in various genomes. It is characterized by its ability to be transcribed from one end to the other, as opposed to traditional non-coding RNAs that are usually polycistronic and have a fixed start and end. LINC01186 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA processing.

Recent studies have suggested that LINC01186 may have potential as a drug target or biomarker. In this article, we will explore the properties and functions of LINC01186, as well as its potential as a drug target and biomarker.

Properties and Functions of LINC01186

LINC01186 is a transcribed RNA molecule that is approximately 290 nucleotides in length. It is expressed in various tissues and cells, including brain, heart, and cancer cells. LINC01186 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA processing.

One of the unique features of LINC01186 is its ability to be transcribed from one end to the other. This property is known as exonception, and it allows LINC01186 to be produced from a single RNA template. LINC01186 has also been shown to have a stable expression pattern in various tissues, which suggests that it may play a role in cell-specific processes.

In addition to its role in cell biology, LINC01186 has also been shown to have potential as a drug target or biomarker. One of the reasons for its potential as a drug target is its unique structure and expression pattern. Unlike traditional non-coding RNAs, LINC01186 has a stable expression pattern in various tissues, which may make it an attractive target for small molecules or other therapeutic agents.

Another potential reason for LINC01186's potential as a drug target is its involvement in various signaling pathways. LINC01186 has been shown to be involved in several signaling pathways, including the NF-kappa pathway and the Wnt pathway. These pathways are involved in various cellular processes, including cell growth, differentiation, and survival. By targeting LINC01186, researchers may be able to develop new treatments for a variety of diseases.

Potential as a Biomarker

In addition to its potential as a drug target, LINC01186 may also have potential as a biomarker. Its stable expression pattern in various tissues and its involvement in various signaling pathways make it an attractive candidate for use as a biomarker.

One of the challenges in the development of biomarkers for various diseases is the difficulty in predicting the response of disease to a particular therapeutic agent. This is because the response of disease can be influenced by a variety of factors, including the stage of the disease, the individual's genetic makeup, and the therapeutic agent used. By using LINC01186 as a biomarker, researchers may be able to overcome these challenges and develop more effective treatments for various diseases.

Conclusion

In conclusion, LINC01186 is a long non-coding RNA molecule that has been identified in various genomes. Its unique structure and expression pattern, as well as its involvement in various cellular processes and signaling pathways, make it an attractive candidate as a drug target or biomarker. Further research is needed to fully understand the properties and functions of LINC01186, as well as its potential as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 1186

The "LINC01186 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01186 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets